NASDAQ:VSTM - Verastem Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.24 -0.24 (-6.90 %)
(As of 03/24/2019 06:58 AM ET)
Previous Close$3.24
Today's Range$3.20 - $3.5368
52-Week Range$2.61 - $10.35
Volume2.42 million shs
Average Volume4.09 million shs
Market Capitalization$239.31 million
P/E Ratio-2.36
Dividend YieldN/A
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. The company is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited, and The Leukemia & Lymphoma Society. The company was founded in 2010 and is headquartered in Needham, Massachusetts.

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:VSTM



Sales & Book Value

Annual Sales$26.72 million
Book Value$1.68 per share


Net Income$-72,430,000.00


Market Cap$239.31 million
Next Earnings Date5/2/2019 (Estimated)

Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) posted its earnings results on Tuesday, March, 12th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Zacks' consensus estimate of ($0.60) by $0.23. The biopharmaceutical company earned $1.21 million during the quarter, compared to the consensus estimate of $5.56 million. View Verastem's Earnings History.

When is Verastem's next earnings date?

Verastem is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Verastem.

What price target have analysts set for VSTM?

7 brokers have issued twelve-month price objectives for Verastem's stock. Their predictions range from $6.00 to $17.00. On average, they expect Verastem's stock price to reach $13.8571 in the next twelve months. This suggests a possible upside of 327.7% from the stock's current price. View Analyst Price Targets for Verastem.

What is the consensus analysts' recommendation for Verastem?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verastem.

What are Wall Street analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:
  • 1. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (3/20/2019)
  • 2. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Our Takeaways From Verastem Investor Day; Reiterate Buy We anticipate duvelisib approval in 4Q18. On May 2, Verastem Oncology held an Analyst and Investor Day in New York and provided an overview on duvelisib’s development and management’s plans for the drug’s commercial launch. Recall, on February 7, Verastem filed a NDA application for duvelisib, the company’s dual PI3K-γ/δ inhibitor, for the treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (r/r CLL/ SLL). The company has also filed for an accelerated approval of duvelisib for the treatment of follicular lymphoma (FL). We note that the FDA has granted a priority review for the duvelisib application, with the PDUFA date scheduled for October 5." (5/3/2018)

Has Verastem been receiving favorable news coverage?

News coverage about VSTM stock has trended somewhat positive on Sunday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Verastem earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Are investors shorting Verastem?

Verastem saw a increase in short interest during the month of February. As of February 28th, there was short interest totalling 23,773,433 shares, an increase of 2.2% from the February 15th total of 23,263,168 shares. Based on an average daily trading volume, of 1,767,653 shares, the days-to-cover ratio is presently 13.4 days. Approximately 33.0% of the shares of the company are sold short. View Verastem's Current Options Chain.

Who are some of Verastem's key competitors?

What other stocks do shareholders of Verastem own?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:
  • Mr. Robert Forrester, Pres, CEO & Director (Age 55)
  • Mr. Richard H. Aldrich Mba, Founder and Consultant (Age 65)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta, Co-Founder
  • Dr. Michelle Dipp, Co-Founder (Age 43)

Who are Verastem's major shareholders?

Verastem's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.62%), Millennium Management LLC (1.69%), Two Sigma Investments LP (1.67%), Dimensional Fund Advisors LP (1.47%), Dimensional Fund Advisors LP (1.47%) and Citigroup Inc. (1.23%). Company insiders that own Verastem stock include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Institutional Ownership Trends for Verastem.

Which major investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Northern Trust Corp, MetLife Investment Advisors LLC, Bank of New York Mellon Corp, Stifel Financial Corp, Algert Global LLC, Raymond James & Associates and Howland Capital Management LLC. View Insider Buying and Selling for Verastem.

Which major investors are buying Verastem stock?

VSTM stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, BlackRock Inc., Citigroup Inc., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Two Sigma Advisers LP and RBF Capital LLC. Company insiders that have bought Verastem stock in the last two years include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Insider Buying and Selling for Verastem.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $3.24.

How big of a company is Verastem?

Verastem has a market capitalization of $239.31 million and generates $26.72 million in revenue each year. The biopharmaceutical company earns $-72,430,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Verastem employs 169 workers across the globe.

What is Verastem's official website?

The official website for Verastem is

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]

MarketBeat Community Rating for Verastem (NASDAQ VSTM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  403 (Vote Outperform)
Underperform Votes:  289 (Vote Underperform)
Total Votes:  692
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by Staff

Featured Article: Conference Calls

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel